ReviewChildren (Basel, Switzerland)2017
Persistent Pulmonary Hypertension in the Newborn.
Review in Children (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Comparative efficacy of volume expansion, inotropes and vasopressors in preterm neonates with probable transitional circulatory instability in the first week of life: a systematic review and network meta-analysis.BMJ paediatrics open · 2024Pooled it
- Melatonin effects on the left ventricular function in neonates with persistent pulmonary hypertension.European journal of pediatrics · 2026Trial
- Nebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial.European journal of pediatrics · 2025Trial
- Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial.BMC pediatrics · 2024Trial
- Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of Newborn: A Pilot Randomized Controlled Trial.Indian journal of pediatrics · 2021Trial
- Vardenafil efficacy for the treatment of persistent pulmonary hypertension of the newborn.World journal of clinical pediatrics · 2026Article
- Persistent Pulmonary Hypertension of the Newborn: A Practical Review for UK Level 2 Local Neonatal Units.Cureus · 2026Review
- Clinical Application of Inhaled Nitric Oxide in Conditions of Excessive Right Heart Load: A Review from Neonatal Pulmonary Hypertension to Perioperative Cardiac Surgery Management.Journal of cardiovascular development and disease · 2026Review
- Recreational Cannabis Use During Human Pregnancy: Its Effects on the Placenta and Endocannabinoid System.International journal of molecular sciences · 2026Review
- Neonatal pulmonary hypertension in the NICU: a 10-year single-center experience.BMC pediatrics · 2025Article
- Severe pulmonary hypertension in a small-for-date neonate with skeletal dysplasia.BMJ case reports · 2025Article
- Predictive Scoring System for Spontaneous Closure of Infant Ventricular Septal Defect: The P-VSD Score.Pediatric cardiology · 2025Article
- Metagenomic Analysis of Gut Microbiome of Persistent Pulmonary Hypertension of the Newborn.Cardiovascular toxicology · 2025Article
- Developing a Neonatal Pulmonary Hypertension Core Outcome Set (NeoPH COS)-A Study Protocol.Pulmonary circulation · 2025Article
- Pulse oximetry in pediatric care: Balancing advantages and limitations.World journal of clinical pediatrics · 2024Article
- Review
- Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns.Pulmonary circulation · 2023Article
- Correlation of ABO blood groups with treatment response and efficacy in infants with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide.BMC pregnancy and childbirth · 2023Article
- Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study.Frontiers in pediatrics · 2023Article
- Risk factors of transient tachypnea of the newborn developing into pulmonary hypertension of the newborn: a case-control study.Asian biomedicine : research, reviews and news · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of failed circulatory adaptation at birth due to delay or impairment in the normal fall in pulmonary vascular resistance (PVR) that occurs following birth. The fetus is in a state of physiological pulmonary hypertension. In utero, the fetus receives oxygenated blood from the placenta through the umbilical vein. At birth, following initiation of respiration, there is a sudden precipitous fall in the PVR and an increase of systemic vascular resistance (SVR) due to the removal of the placenta from circulation. There is dramatic increase in pulmonary blood flow with a decrease in, and later reversal of shunts at the foramen ovale and ductus arteriosus. The failure of this normal physiological pulmonary transition leads to the syndrome of PPHN. PPHN presents with varying degrees of hypoxemic respiratory failure. Survival of infants with PPHN has significantly improved with the use of gentle ventilation, surfactant and inhaled nitric oxide (iNO). PPHN is associated with significant mortality and morbidity among survivors. Newer agents that target different enzymatic pathways in the vascular smooth muscle are in different stages of development and testing. Further research using these agents is likely to further reduce morbidity and mortality associated with PPHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.